行情

CELG-RT

CELG-RT

Celgene
NYSE

实时行情|Nasdaq Last Sale

0.4555
-0.0164
-3.48%
已收盘, 16:00 04/01 EDT
开盘
0.4555
昨收
0.4719
最高
--
最低
--
成交量
258
成交额
--
52周最高
1.240
52周最低
0.2711
市值
3.36亿
市盈率(TTM)
0.0589
分时
5日
1月
3月
1年
5年

CELG-RT 新闻

更多
  • 周一特斯拉股价报收419.22美元 创历史新高
  • 新浪科技 · 2019/12/23 22:14
  • 贸易缓和提振能源需求 原油微幅收涨
  • 新浪美股 · 2019/12/23 21:50
  • 牛市还能牛多久?华尔街示意明年上半年将进一步上涨
  • 新浪财经综合 · 2019/12/23 21:46
  • 奈飞十年:一家公司如何改变我们的电视观看方式
  • 新浪美股 · 2019/12/23 20:28

所属板块

制药
-2.55%
制药与医学研究
-2.96%

热门股票

代码
价格
涨跌幅

CELG-RT 简况

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
展开

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CELG RT股票新闻,以帮助您做出投资决策。